Lack of Interaction of Gabapentin with Carbamazepine or Valproate

Louis L. Radulovic, B. J. Wilder, Ilo E. Leppik, Howard N. Bockbrader, Tsun Chang, Edward L. Posvar, Allen J. Sedman, Basim M. Uthman, Gary R. Erdman

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


Summary: Gabapentin (GBP) studies were conducted in patients with epilepsy receiving carbamazepine (CBZ, n= 12) or valproate (VPA, n = 14) monotherapy. The effects of GBP coadministration on steady‐state CBZ or VPA concentrations and of these antiepileptic drugs (AEDs) on GBP pharmacokinetics were investigated. GBP (400 mg) was coadministered every 8 h for 3% days with CBZ or for 5 1/3 days with VPA. GBP was well tolerated. Mean steady‐state plasma CBZ/CBZ‐10, ll‐epoxide (CBZ‐E) and serum VPA concentrations before, during, and after GBP administration were not significantly different. Mean steady‐state GBP pharmacokinetic parameters during CBZ or VPA coadministration were similar to steady‐state parameters reported in healthy subjects. Thus, no pharmacokinetic interaction exists between CBZ or VPA and GBP. No dosage adjustment is necessary when GBP and CBZ or VPA are coadministered.

Original languageEnglish (US)
Pages (from-to)155-161
Number of pages7
Issue number1
StatePublished - Jan 1994
Externally publishedYes


  • Anticonvulsants
  • Drug interaction‐carbamazepine
  • Gabapentin
  • Pharmacokinetics
  • Valproate‐Drug toxicity

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Lack of Interaction of Gabapentin with Carbamazepine or Valproate'. Together they form a unique fingerprint.

Cite this